Cerevast Therapeutics provides non-invasive SonoLysis therapy for vascular disorders using proprietary technology.
Cerevast Therapeutics, founded in September 2009, is a medical technology company focused on developing non-invasive SonoLysis therapies for treating acute ischemic stroke and other vascular disorders. Their flagship product, the ClotBust-ERTM, is an ultrasonic headframe designed to be easily deployed by emergency room staff to administer ultrasound energy for SonoLysis therapy. The company aims to revolutionize emergency stroke treatment with its operator-independent device, ensuring rapid and safe intervention.
Notable figures associated with Cerevast include its experienced management team and board of directors, who bring extensive expertise in medical technology and healthcare innovation. The company has garnered attention from prominent investors in the medical field, supporting its research and development efforts. Key achievements include advancing their pipeline programs in retinal vein occlusion and transcranial ultrasound therapies. Cerevast's impact lies in its potential to significantly improve outcomes for stroke patients through innovative, non-invasive treatment solutions.
Cerevast Therapeutics' most recent funding round was for $11.4M (USD) in March 2015.
As of Mar 6, 2015, Cerevast Therapeutics has disclosed funding of $24.4M (USD).

SonoVascular
sonovascular.com

CereVasc
cerevasc.com
NeuroVasx
Waveclear

Cognition Medical
Cervel Neurotech
cervel.com

NeuRx Medical
neurxmed.com

Rapidpulse
rapidpulsemed.com

Cerebrotech Medical Systems

Nervive

Imperative Care
imperativecare.com

Vibrato Medical
vibratomedical.com
Insera Therapeutics

ZetrOZ Systems
zetroz.com

Provisio Medical
Sonogenix

Neurosonics Medical

SonALAsense
sonalasense.com

Vave Health
vavehealth.com

MIVI Neuroscience
mivineuro.com